Alzheimer's Disease

Why trials studying Alzheimer's Disease stopped, in this sample of ClinicalTrials.gov.

17 stopped trials with a clear reason; 65% ended for non-scientific reasons.

Trials

• A Phase III Multi Regional Clinical Trial (MRCT) of Tricaprilin in Mild to Moderately Severe Probable Alzheimer's Disease With Optional Open Label Extension
  NCT04187547 · WITHDRAWN · other
  “Study replaced with a new study”
• Open-Label Extension of the PTI-125-04 Study in Mild-to-Moderate Alzheimer's Disease
  NCT05352763 · TERMINATED · funding business
  “Sponsor Decision”
• Induction and Recognition of Emotions
  NCT04353947 · WITHDRAWN · logistics pi
  “COVID 19”
• An Extension Study of V203-AD Study to Evaluate the Safety, Tolerability, Immunogenicity, and Efficacy of UB-311
  NCT03531710 · TERMINATED · funding business
  “United Neuroscience has decided to terminate V203-AD-EXT study based on a treatment assignment error”
• A Study to Evaluate the Long-term Safety and Tolerability of Lu AF20513 and the Antibody Response in Patients With Alzheimer's Disease (AD)
  NCT03668405 · TERMINATED · other
  “New data: The study was terminated based on new efficacy data from another study”
• An Open-Label Crenezumab Study in Participants With Alzheimer's Disease
  NCT03491150 · TERMINATED · futility
  “This study was discontinued due to an interim analysis in the BN29552 study, which indicated that Crenezumab was unlikely to meet its primary endpoint.”
• BAC in Patient With Alzheimer's Disease or Vascular Dementia
  NCT02467413 · WITHDRAWN · slow accrual
  “The study was withdrawn before participants were enrolled.”
• A Study Evaluating the Efficacy and Safety of Crenezumab Versus Placebo in Participants With Prodromal to Mild Alzheimer's Disease (AD).
  NCT02670083 · TERMINATED · futility
  “This study was discontinued due to an interim analysis in this study, which indicated that Crenezumab was unlikely to meet its primary endpoint.”
• Reminiscence, Anxiety and Early Alzheimer's Disease
  NCT02319681 · WITHDRAWN · logistics pi
  “PI relocated to UNCP; Study is not being transferred”
• Safety Study of MT-4666 in Subjects With Alzheimer's Disease
  NCT02327182 · TERMINATED · slow accrual
  “This study was terminated due to the benefit-risk balance of MT-4666.”
• Open-Label Study of Leuco-methylthioninium Bis(Hydromethanesulfonate) (LMTM) in Subjects With Alzheimer's Disease or Behavioral Variant Frontotemporal Dementia (bvFTD)
  NCT02245568 · TERMINATED · logistics pi
  “This study has been terminated for administrative reasons only.”
• GSK2647544 RD, DDI in Healthy Young and Elderly Volunteers
  NCT01978327 · TERMINATED · futility
  “Given the strength of CYP3A4 inhibition observed in Cohort 1, there is no rationale to investigate higher doses of GSK2647544 in the following two cohorts”
• Biodistribution of 11C-PIB PET in Alzheimer's Disease, Frontotemporal Dementia, and Cognitively Normal Elderly
  NCT00811122 · TERMINATED · other
  “A Fluorine-18 labeled version of the radiopharmaceutical (Flutemetamol) became available. This version is far superior to the Carbon-11 PiB. There is no need to make this compound available any longer.”
• Memantine and Antipsychotics Use
  NCT00649220 · TERMINATED · slow accrual
  “Study terminated due to too slow enrollment”
• Lutein and Alzheimer's Disease Study
  NCT00596024 · TERMINATED · slow accrual
  “Lack of enrollment”
• Effects Of Rosiglitazone (Extended Release Tablets) On Cerebral Glucose Utilisation And Cognition Alzheimers Disease
  NCT00334568 · TERMINATED · slow accrual
  “Slow recruitment”
• A Study of the Effectiveness and Safety of Risperidone Versus Placebo in the Treatment of Patients With Hallucinations and Delusions Associated With Alzheimer's Disease
  NCT00287742 · TERMINATED · funding business
  “A decision was made to discontinue the study due to a change in the strategic direction of the company.”

Reasons are labeled automatically and are unverified. See the methodology. This is research information, not medical advice. Search the full database.